Surveillance of Bromocriptine in Pregnancy

Turkalj, Ivan; Braun, P.; Krupp, P.

doi:10.1097/00006254-198301000-00017

Cited by 7 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No evidence of increased rates of abortion or congenital malformation was reported. 63 Before this treatment can be recommended as a routine strategy, there is a need for a larger randomized trial, although some physicians currently add bromocriptine to conventional therapy on an individual basis.…”

Section: New Therapeutic Strategiesmentioning

confidence: 99%

Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy

Sliwa

Hilfiker‐Kleiner

Petrie

et al. 2010

European J of Heart Fail

896

983

View full text Add to dashboard Cite

Peripartum cardiomyopathy (PPCM) is a cause of pregnancy-associated heart failure. It typically develops during the last month of, and up to 6 months after, pregnancy in women without known cardiovascular disease. The present position statement offers a state-of-the-art summary of what is known about risk factors for potential pathophysiological mechanisms, clinical presentation of, and diagnosis and management of PPCM. A high index of suspicion is required for the diagnosis, as shortness of breath and ankle swelling are common in the peripartum period. Peripartum cardiomyopathy is a distinct form of cardiomyopathy, associated with a high morbidity and mortality, but also with the possibility of full recovery. Oxidative stress and the generation of a cardiotoxic subfragment of prolactin may play key roles in the pathophysiology of PPCM. In this regard, pharmacological blockade of prolactin offers the possibility of a disease-specific therapy.--

show abstract

Section: New Therapeutic Strategiesmentioning

confidence: 99%

Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy

Sliwa

Hilfiker‐Kleiner

Petrie

et al. 2010

European J of Heart Fail

896

983

View full text Add to dashboard Cite

show abstract

“…Pituitary imaging is necessary when secondary causes for hyperprolactinemia have been excluded. Dopaminergic drugs often restore normal ovulatory cycles and fertility [6].…”

Section: Causes Of Hormonal Infertilitymentioning

confidence: 99%

Management of female infertility from hormonal causes

Luciano

Lanzone

Goverde

2013

Intl J Gynecology & Obste

View full text Add to dashboard Cite

Hormonal causes of female infertility involve ovulatory dysfunctions that may result from dysfunction of the hypothalamic-pituitary-ovarian axis, peripheral endocrine glands, nonendocrine organs, or metabolic disorders. It is important to think of anovulation not as a diagnosis but as a symptom of a metabolic or endocrine disorder that requires a thorough diagnostic evaluation to identify the specific cause and to implement effective therapies that assure the best possible pregnancy outcome and avoid long-term adverse health consequences. In most instances, the medical history points to the underlying dysfunction, which can usually be confirmed with laboratory or imaging tests. For more challenging cases, more extensive evaluations may be needed, including perturbation studies. Nevertheless, the management of anovulatory infertility is gratifying because its causes are often manifest and the treatment usually results in resumption of ovulatory cycles, restoration of fertility, and healthy offspring through natural conception without requiring expensive and intrusive assisted reproductive technologies.

show abstract

“…Bromocriptine is the dopamine agonist of choice in women desirous of pregnancy and reassuring data concerning the safety of conception following bromocriptine for ovulation induction has now been documented since the 1980s. 22 Cabergoline is a more modern dopamine agonist and data concerning safety in pregnancy are less complete, but nonetheless, positive suggesting that if a woman is intolerant or resistant to bromocriptine, cabergoline is a reasonable alternative. 23 Dopamine agonists may be ceased when pregnancy is confirmed, although some clinicians will continue medication throughout pregnancy in patients with larger tumours or where optic chiasm compromise is possible or has been previously demonstrated.…”

Section: Prolactinomas In Pregnancymentioning

confidence: 99%

Dopamine agonists in the treatment of prolactinoma: are they still first choice?

Ogilvie¹,

Milsom²

2011

Internal Medicine Journal

View full text Add to dashboard Cite

Dopamine agonist therapy has been the cornerstone treatment for prolactinoma since the 1970s, replacing surgery in the primary management of this condition. These agents are effective in the management of prolactin excess, have a low side-effect profile, and in some cases may even be curative. However, recent studies of high dose dopamine agonists used in Parkinson's disease have raised the possibility that these drugs may be associated with cardiac valvulopathy. This paper discusses the modern use of dopamine agonists in a patient with prolactinoma.

show abstract

Surveillance of Bromocriptine in Pregnancy

Cited by 7 publications

References 0 publications

Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy

Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy

Management of female infertility from hormonal causes

Dopamine agonists in the treatment of prolactinoma: are they still first choice?

Contact Info

Product

Resources

About